Supplementary Table S2. Adverse events (regardless of relationship to study drug) by preferred term in ≥10% of patients in total phase 1 population

AE[a]	15 mg: PiB (n=3)	30 mg: PiB (n=3)	60 mg: PiB (n=4)	120 mg: PiB (n=3)	180 mg: PiB (n=3)	180 mg: Cap (n=14)	180 mg: PiB + Cap (total: n=17)	270 mg: Cap (n=6)	210 mg: Cap (n=9)	Phase 1 total (N=45)
Total treatment-emergent AEs, n	17	13	23	21	19	110	129	59	149	411
Patients with ≥1 treatment-emergent AE, n (%)	3 (100)	3 (100)	4 (100)	3 (100)	3 (100)	14 (100)	17 (100)	6 (100)	9 (100)	45 (100)
Fatigue	0	1 (33)	2 (50)	0	0	4 (29)	4 (24)	2 (33)	6 (67)	15 (33)
Vomiting	3 (100)	0	1 (25)	1 (33)	1 (33)	3 (21)	4 (24)	2 (33)	3 (33)	14 (31)
Nausea	1 (33)	0	2 (50)	0	0	2 (14)	2 (12)	2 (33)	5 (56)	12 (27)
Anemia	1 (33)	0	1 (25)	0	0	4 (29)	4 (24)	2 (33)	2 (22)	10 (22)
Pruritus	0	0	1 (25)	2 (67)	0	4 (29)	4 (24)	0	3 (33)	10 (22)
Decreased appetite	0	1 (33)	1 (25)	0	0	3 (21)	3 (18)	0	4 (44)	9 (20)
Peripheral edema	0	0	2 (50)	0	0	2 (14)	2 (12)	1 (17)	2 (22)	7 (16)
Maculopapular rash	0	0	0	1 (33)	0	3 (21)	3 (18)	3 (50)	0	7 (16)
Cough	0	0	2 (50)	1 (33)	0	1 (7)	1 (6)	1 (17)	1 (11)	6 (13)
Diarrhea	1 (33)	1 (33)	0	0	1 (33)	1 (7)	2 (12	0	2 (22)	6 (13)
Dyspnea	0	0	0	0	1 (33)	3 (21)	4 (24)	0	2 (22)	6 (13)
Increased lipase	0	0	1 (25)	0	0	0	0	2 (33)	3 (33)	6 (13)
Back pain	0	0	0	0	1 (33)	1 (7)	2 (12)	1 (17)	2 (22)	5 (11)
Headache	1 (33)	0	1 (25)	0	0	2 (14)	2 (12)	0	1 (11)	5 (11)
Hypotension	0	0	0	0	0	3 (21)	3 (18)	0	2 (22)	5 (11)
Lymphopenia	1 (33)	1 (33)	0	1 (33)	0	0	0	2 (33)	0	5 (11)
Oropharyngeal pain	0	0	1 (25)	1 (33)	0	1 (7)	1 (6)	0	2 (22)	5 (11)
Stomatitis	0	0	0	2 (67)	0	1 (7)	1 (6)	2 (33)	0	5 (11)

[a]Patients are counted only once for each AE preferred term. Cap, capsule.